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The objectives of this review are to assess the current state of hypertonic saline as a prehospital resuscitation
fluid in hypotensive trauma patients, particularly after the 3 major Resuscitation Outcomes Consortium trauma
trials in the US and Canada were halted due to futility. Hemorrhage and traumatic brain injury are the leading
causes of death in both military and civilian populations. Prehospital fluid resuscitation remains controversial in
civilian trauma, but small-volume resuscitation with hypertonic fluids is of utility in military scenarios with
prolonged or delayed evacuation times. A large body of pre-clinical and clinical literature has accumulated over
the past 30 years on the hemodynamic and, most recently, the anti-inflammatory properties of hypertonic
saline, alone or with dextran-70. This review assesses the current state of hypertonic fluid resuscitation in the
aftermath of the failed Resuscitation Outcomes Consortium trials.
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& INTRODUCTION
Traumatic injury is the leading cause of death in adults
,44 years old, and its incidence is increasing worldwide (1).
Among traumatic injuries, hemorrhage and traumatic brain
injury are leading causes of death in both the military and
civilian populations, with hemorrhage-related deaths occur-
ring early (2-4). Both the early control of bleeding and
resuscitation, which restores blood volume and re-estab-
lishes tissue perfusion to vital organs, are paramount.
However, the use of fluid for prehospital resuscitation of
trauma patients in the civilian sector remains controversial,
based on short transport times, the likelihood of infusing
only small volumes of fluid and the concern of causing more
bleeding in cases of uncontrolled or non-compressible
hemorrhage. In the military, well-recognized limitations
make far-forward resuscitation difficult (5-7). Nevertheless,
the challenges of prehospital fluid resuscitation are further
highlighted by evidence from experimental animals, which
suggests that interventions to re-establish homeostasis may
need to be initiated within 30 minutes after injury to assure
survival (8).
In general, the ideal resuscitation fluid to treat the
severely injured, hypotensive trauma patient should be
safe, should expand blood volume, should improve oxygen
delivery and possibly reduce oxygen demand, should not
increase bleeding and should be easy to administer as well
as be able to achieve these goals with a small volume.
Research into the possibility of such a fluid was stimulated
more than 30 years ago by encouraging results observed in
an early study in hemorrhaging dogs (9), which were
treated with a 4 ml/kg bolus of 7.5% hypertonic saline (HS).
This bolus volume was equivalent to 10% of the shed blood
volume, and the dogs experienced rapid improvements in
blood pressure, cardiac output and, most importantly,
survival. Later experiments performed in sheep (10) and
swine (11) added 6% dextran-70 to sustain these improved
hemodynamics, and this solution, HSD, attracted great
interest from the military. Subsequent preclinical studies in
different controlled hemorrhage models and animal species
have shown similar benefits in outcomes with doses as low
as 4 ml/kg (12). No potential resuscitation fluid has under-
gone as extensive a pre-clinical evaluation and safety
schedule as HSD.
The initial interest in HS and HSD focused on their
physical and chemical abilities to rapidly expand plasma
volume (13). This volume expansion was greater in
hypotensive subjects than in normotensive subjects (12,14),
and these effects were more pronounced when compared
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with current standard of care fluids, such as normal saline
(NS) or lactated Ringer’s (LR) (15). In addition, these
products did not require refrigeration and were stable for
more than 2 yr at a wide range of temperatures.
Other studies have found that HS and HSD reduce
peripheral vascular resistance and improve microcirculatory
flow, leading to improved tissue perfusion and oxygen
delivery (16). Further studies in experimental animals
concluded that HSD should be the first resuscitation fluid
administered (17) and that doses could be adjusted to sustain
animals, even in uncontrolled hemorrhage models (18-20).
Most recently, attention has focused on other pharmaco-
logic actions of hypertonic fluids, particularly their effects
on immune function. In part, this work arose from studies
on the improved microcirculation associated with hyper-
tonic fluids (16,21-22) because these fluids reduce neutro-
phil rolling and sticking to endothelial cells in blood vessels
(23-24). Taken together, the body of literature suggests that
HS, if provided early, could inhibit the immune suppression
that is associated with hemorrhagic shock, and based on
several in vitro studies, may have direct protective effects on
immune cells (23). Overall, these data on immune function
further support that initial, early HS resuscitation would be
of greater benefit than infusion after the administration of
conventional fluids and that the modulation of immune
function by HS may reduce secondary medical complica-
tions (25-28).
Clinical studies
A series of clinical studies were conducted in trauma
patients in the late 1980s and early 1990s. In general, the
trials were designed so subjects received a 250 ml bolus of
HSD or standard of care crystalloid, followed by as much
crystalloid as deemed medically appropriate. In most of the
available studies, hypertonic solutions were administered
within 2 hr following injury. To summarize, in 9 prospective
trials with more than 900 patients who were treated with
HSD, a mean survival benefit of 3.6% was observed. While 1
study reported improved survival at 24 hr (29), the others
were inconclusive. In general, prehospital studies, rather
than emergency department studies, suggested a greater
benefit if the hypertonic fluids were the first resuscitation
fluid used before the patient went into profound shock.
Numerous retrospective reviews concluded that HSD had a
favorable effect on survival, but statistical significance could
not be demonstrated. Interestingly, HSD showed significance
for efficacy in subpopulations of more severely injured
patients (e.g., patients with head injuries (TBI) and patients
requiring blood transfusions or surgery) (14,30-34). In
addition, in a trial by Vassar et al, (35), no differences were
observed between patients who received HS vs. patients who
received HSD, so the authors concluded that in the civilian
population, with relatively short evacuation times, HS was
sufficient. Importantly, all of these clinical trials confirmed
that the use of HSD in trauma patients was safe (36).
As mentioned above, an early clinical study indicated that
in patients with severe TBI, those patients who received
HSD were twice as likely to survive to hospital discharge
compared with those patients who received standard
crystalloid (37). General clinical interest in the potential
benefits of hypertonic fluids for the treatment of TBI has
centered on these fluids’ ability to support blood pressure
and improve cerebral perfusion pressure without raising
intracranial pressure and causing cerebral edema, which are
common side effects with standard crystalloids. In addition,
studies have suggested that HS is a viable alternative to
mannitol for treating refractory intracranial hypertension in
TBI patients (38-40). However, in a clinical study of
comatose TBI patients who were treated prehospital with
a 250 ml bolus of HS vs. LR followed by additional standard
crystalloid infusion, no significant differences were noted
between groups to hospital discharge or in neurological
function at 6 mo (41). However, in a retrospective cohort
analysis of the effects of HSD in TBI patients with
hypotension, Wade et al. (42) concluded that such patients
who received HSD were twice as likely to survive as
patients who received standard crystalloid resuscitation. In
addition, Baker et al. (34) reported that HSD reduced several
biomarkers of brain injury in TBI patients, suggesting that
HSD could lessen brain damage.
The resuscitation outcomes consortium (ROC) trials
Based on the continuing controversy over hypertonic
fluids and the inconclusive results of previous clinical
studies, the ROC trials, which consisted of 2 separate
randomized, double-blind control, multicenter protocols,
were initiated for the study of 2 subpopulations of trauma
patients: patients with hypovolemic shock and patients with
severe TBI (43). Each trial had 3 arms, and the patients were
randomized within 4 hr of injury for treatment with a 250 ml
bolus of HS, HSD or normal saline (NS), followed by
additional crystalloid as determined by medical need.
However, patients were excluded if they received .
2000 ml of any fluid prior to receiving the test product. The
feasibility of performing these studies in TBI patients was
confirmed (44-45). The primary endpoints were 28 d survival
in the hypovolemic shock patients and Extended Glasgow
Outcome Scale (GOSE) score at 6 mo in the TBI study (43).
Secondary outcomes included incidence of acute respiratory
distress syndrome (ARDS), multi-organ failure, infection,
number of ventilator days and physiologic and functional
outcomes in the first 28 d. In the hypovolemic shock study,
895 patients were randomized, and 220, 256 and 375
patients were included for analysis in the HSD, HS and NS
groups, respectively (46). The study was stopped early
after obtaining only 23% of the proposed sample size,
based on the Data Safety Monitoring Board for futility, due
to the unlikelihood of obtaining a statistically significant
improvement in 28-d survival in the hypertonic groups
over NS and possible safety concerns. No differences in 28-
d survival were noted among the groups. There were also
no differences among the groups in 6 hr survival time or
ARDS-free 28-d survival time. Of concern was a higher
mortality rate in the 2 HS groups (HSD 10% and HS 12.2%),
compared with NS (4.8%), in which patients did not receive
a blood transfusion in the first 24 hr.
The TBI trial was designed to enroll 2122 patients, but it
was also stopped for futility in showing benefit after
randomization of 1331 patients and analysis of 1087 patients
(47). These patients had TBI and were not in hypovolemic
shock. In this patient population, no significant differences
among the groups were noted for 28-d survival or 6 mo
neurological outcomes, as determined by distribution of
GOSE category or Disability Rating Score.
Concluding remarks
Despite a huge body of literature showing that HSD and HS
improve hemodynamic and metabolic responses, modulate
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immune function and reduce brain edema in a number of
experimental injury models and several small and large
animal species, translating these results into improved
survival in clinical trials in hemorrhagic shock and TBI
has been difficult. Considering the heterogeneity of injury,
injury severity and age of the trauma patients, it is not
surprising that all the clinical trials to date have had
several limitations, such as being underpowered to show
improved survival or not having been focused on the
trauma population most likely to benefit. A clear
difference between the preclinical studies and the clinical
trials is the dose. In the majority of animal studies, HS or
HSD was administered primarily as a single 4 ml/kg
bolus dose, whereas in the clinical trials, a 250 ml bolus
(approximately 3.6 ml/kg in a 70 kg person) was followed
by additional crystalloid. It was shown previously that the
benefit (e.g., volume sparing) of hypertonic infusion was
lost if the infusion rate was too slow or if it was followed
immediately by standard crystalloid (48). In addition,
none of the clinical trials reported the body weights of the
patients, so it is unknown whether the per kg body
weight dose was similar to the doses administered in the
pre-clinical animal studies. Previous data in swine
hemorrhage models indicated that the survival benefit of
hypertonic fluids could be lost at doses #2 ml/kg (11).
Because HS and HSD are efficient volume expanders and
because they expand plasma volume better in hypovo-
lemic than normovolemic conditions, concerns were raised
regarding clinical trials in which the additional fluids in
severely injured hypovolemic patients could worsen the
hemodilution of blood clotting factors and lead to more
bleeding. However, none of the clinical trials has demon-
strated greater bleeding in any patient treated with
hypertonic fluids. In fact, it is the bleeding patient who
seems to benefit most from receiving HS or HSD as the
initial resuscitation fluid.
The observation in the trial by Bulger et al. (46) of greater
mortality after hypertonic fluid infusion in a subgroup of
trauma patients who did not receive blood transfusions in
the first 24 hr was most disturbing and was never predicted
by the large body of preclinical data nor by any of the
previous trauma trials. It is possible that based on volume
expansion properties and the additional crystalloid fluid
noted, certain trauma patients with pre-existing comorbid-
ities could have developed heart failure due to fluid
overload. Another very plausible explanation was offered
by Holcroft (49) with regard to the well-described properties
of HS or HSD of dilating resistance vessels in the skin,
resulting in intense flushing. Holcroft postulated that
patients with occult abdominal bleeding who received HS
or HSD prehospital would have presented to the emergency
department with maintained blood pressure and the
appearance of well-perfused skin, giving the care providers
the impression that the patient did not need hemorrhage
control or blood, thus resulting in the higher mortality
observed. This argument reinforces the suggestion that
when hypertonic fluids are infused as a bolus, the use of
blood pressure to monitor the patient’s status is mean-
ingless.
Today, some civilian centers have used FDA-approved 3%
or 5% HS as the initial treatment for patients with a head
injury to reduce intracranial pressures and improve cerebral
blood flow, with the suggestion that these solutions can be as
beneficial as the 7.5% product, which is not FDA-approved
(50-51). Although the argument continues over the validity of
using the 28-d survival endpoint to evaluate resuscitation
fluid, it is clear that hypertonic fluids improve secondary
endpoints in both hypovolemic trauma patients and in
patients with TBI. In addition, none of the standard of care
solutions used today have been required to demonstrate
improvement in the primary outcomes of the hypertonic
studies. If HS finds some utility in the treatment of civilian
trauma, small-volumeHSD remains the fluid of choice for the
military, in which its longer duration of action is beneficial in
the face of longer evacuation times in asymmetric battlefields.
Over the past few years, the concept of fluid resuscitation has
changed to the paradigm of damage control resuscitation
(DCR), with more judicious use of early blood products and
low-volume asanguinous fluids to maintain blood-clotting
factors and to improve the metabolic consequences of and
immune dysfunction caused by hemorrhagic shock. Current
efforts to move DCR practices into the prehospital arena have
begun with the development of modern dry plasma.
Discussions have already begun with regard to pursuing a
hypertonic plasma, which may contain 3% NaCl. Thus, as
small-volume fluids, HS and HSD would be compatible with
the concept of permissive hypotension in the prehospital
setting and would fit in the overall scheme of DCR.
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